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Aconitase 2 (ACO2) encodes the mitochondrial aconitase (ACO2), an enzyme catalyzing
interconversion of citrate into isocitrate in the Krebs cycle. ACO2mutations have been initially
associated with infantile cerebellar-retinal degeneration combining optic atrophy, retinal
degeneration, severe encephalopathy, epilepsy, and cerebellar ataxia1–3; subsequently, ACO2
mutations have also been associated with milder presentations including isolated optic atrophy2
or cerebellar ataxia without optic atrophy.4 We report here a patient presenting with a novel
ACO2 phenotype associating optic atrophy with spastic paraplegia.
Methods
Mini-exome sequencing by exon capture (TruSight One Sequencing Panel kit—Montpellier
NGS platform) was performed in a patient with familial syndromic optic atrophy. Written
informed consent was obtained. Aconitase enzymatic activity was measured as previously
described.5
Case report
A now 56-year-old white lady issued from a nonconsanguineous union presented because of
severe optic atrophy and spastic paraplegia. Her symptoms had been slowly progressive since
infancy and associated with delayed motor (walking at about 3 years) and mental development.
An ophthalmologist (C.H.) first examined her at the age of 38 years because of her visual
problems. She came to the neurologic clinic at the age of 49 years because of aggravation of
the spastic paraplegia, requiring a walking aid. She currently presents with mild cognitive
involvement allowing a relatively autonomous life with a sheltered social work. Her sister (not
directly examined) has a similar but more severe clinical presentation with visual problems,
spasticity, and mental retardation. Cerebral MRI showed mild vermian cerebellar atrophy and
nonspecific T2 and fluid-attenuated inversion recovery hyperintensities in cerebellar dentate
nuclei and supratentorial white matter (figure, A–D). Neurologic examination revealed severe
visual impairment, mild upper limb ataxia, diffuse hyperreflexia, and severe spastic paraplegia
with bilateral extensor plantar reflex. Ophthalmological evaluation confirmed the presence of
bilateral optic atrophy without retinal involvement, globally stable since first examination at the
age of 38 years. Visual acuity was severely reduced (right eye: counts the fingers at 30 cm; left
eye: counts the fingers at 1 m). The patient did not present any signs of peripheral neuropathy,
and the EMG was normal. Mini-exome analysis identified compound heterozygous mutations
in the ACO2 gene (c.2135C>T [p.(Pro712Leu)]4; c.940+5G>C) in the patient and her
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Figure Cerebral MRI and molecular and enzymatic analysis
Mild vermian cerebellar atrophy (A, axial FLAIR w.i.); bilateral dentate hyperintensities (white arrow in B, axial FLAIR w.i., and D, sagittal FLAIR w.i); and
supratentorial white matter hyperintensities (white arrow in C, axial FLAIR w.i). (E) Pedigree showing segregation of the disease with mutation c.940+5G>C
causing the in-frame skipping of exon 7 and with mutation c.2135C>T causing the p.(Pro712Leu) missense change (P712L). Analysis of reverse transcription
PCR (RT-PCR) products of the patient skin fibroblasts (F): the c.940+5G>C mutation (SplicePort score reduction from 1.17 to 0.21) affects exon 7 splicing and
results in an abnormal RT-PCR fragment of 980 bp (arrow), whereas only the normal product of 1,085 bp is seen for control fibroblasts. Sequence of RT-PCR
products (G): skipping of exon 7 leading to an in-frame deletion of 35 amino acids (p.[Gly279_Glu313del]). (H) Sanger sequencing results of parents and
patients: Both patients are compoundheterozygous for themutations c.940+5G>C and p.(Pro712Leu), themother (I.1) is a heterozygous carrier for the c.940+
5G>C mutation, and the father (I.2) is a heterozygous carrier for the p.(Pro712Leu) mutation. (I) Mitochondrial aconitase activity is measured for 10 minutes
(citrate injection), followed by isocitrate dehydrogenase activity for 2 minutes (isocitrate injection) through NADPH production in fibroblasts. Patient II.4
aconitase activity (red line) is reduced to about 50% of controls (black line), whereas isocitrate dehydrogenase activity, used for normalization, is similar to
controls. (J): Predicted location of mutations on the ACO2 enzyme and substrate and cofactor binding sites. Stripe box: mitochondrial targeting signal;
*Substrate binding sites; ©Iron-sulfur binding sites; highlighted mutations: present report; boxed (dotted) mutations: optic atrophy 9 (OPA9) phenotype;
underlined mutations: infantile cerebellar-retinal degeneration phenotype (ICRD). FLAIR = fluid-attenuated inversion recovery.
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affected sister (figure, E–H); the second mutation involves
exon 7 donor splice site and causes the in-frame skipping of
exon 7, as confirmed by reverse transcription PCR (RT-PCR)
analysis on patient’s skin fibroblasts (figure, F and G). No
relevant variants were found in other genes causing isolated or
syndromic optic atrophy. Total aconitase enzymatic activity
on the patient’s cultured skin fibroblasts showed a 50% de-
crease in activity in the presence of citrate and a 40% decrease
in activity in the presence of cis-aconitate (compared with
isocitrate dehydrogenase activity as a reference) (figure, I),
suggesting, in the presence of the two ACO2 mutations,
ACO2 impairment. We did not find mt-DNA depletion in the
patient’s fibroblasts and leukocytes (not shown).
Discussion
In this report, we expand the phenotype of ACO2 mutations
describing a patient with severe spastic paraplegia and
symptomatic optic atrophy; the patient also had a relatively
mild cognitive involvement, while cerebellar involvement,
usually associated withACO2mutations,1–4 was clinically very
mild, although present at the imaging level.
The pathogenicity of the mutations was confirmed by the
segregation in the family and by the quantification of the
enzymatic activity, consistent with deficiencies observed in
previously reported milder ACO2 cases.2 Moreover, the
pathogenicity of the intronic mutation was confirmed by
RT-PCR studies.
The presently described phenotype might evoke a spastic
paraplegia, optic atrophy, and peripheral neuropathy–like
phenotype6 but differs because of absent peripheral neuropathy.
Mutations in genes coding for enzymes of the Krebs cycle are
globally rare and are often responsible for a large spectrum of
disease ranging from severe early-onset encephalopathy to
various types of tumors.7 The pathophysiologic mechanism
could be disruption of energy metabolism and oxidative
phosphorylation, but defects in mitochondrial DNA mainte-
nance have also been identified, notably for ACO24 and
SUCLA2.8
Ocular phenotypes have already been reported in ACO2
deficiency, with optic atrophy and retinal dystrophy,1 but also
in isocitrate dehydrogenase deficiency, with pigmentary
retinopathy, succinyl-CoA synthetase deficiency, with
ophthalmoplegia, and succinate dehydrogenase deficiency
(SDH), with optic atrophy and pigmentary retinopathy.
Slowly progressive spastic paraplegia has never been reported
in ACO2 or in other Krebs cycle defects. Moreover, patients
with Krebs cycle defect and isolated organ-specific in-
volvement or milder survival into adulthood are rare and were
described for SDH, succinyl-CoA synthetase deficiency
(SUCLA2), and fumarase deficiency. The presently reported
patient underscores striking variable clinical presentations
resulting from ACO2 mutations, ranging from early-onset
severe epileptic encephalopathy with cerebello-ocular syn-
drome (ICRD)1 to isolated optic atrophy (OPA9),2 complex
ataxia without optic atrophy,4 and now spastic paraplegia and
optic atrophy with survival into adulthood (figure, J). The
detection of these milder and new phenotypes is possible
because of next-generation sequencing techniques. Milder
phenotypes are generally associated, as this is the case of our
patient, with moderate residual ACO2 enzymatic activity2;
however, a case of a relatively mild phenotype despite marked
ACO2 enzymatic activity reduction has already been repor-
ted, suggesting complex genotype-phenotype correlations.4
In addition to severe encephalopathic and cerebello-ocular
phenotypes, ACO2 mutations should be investigated in the
presence of milder phenotype with slowly progressive spastic
paraplegia and optic atrophy.
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